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A B ST R A C T  
 
Chronic Kidney Disease affects approximately 10% of the world’s adult population: it is within the 
top 20 causes of death worldwide, and its impact on patients and their families can be devastating. 
World Kidney Day and International Women’s Day in 2018 coincide, thus offering an opportunity to 
reflect on the importance of women’s health and specifically their kidney health, on the community, 
and the next generations, as well as to strive to be more curious about the unique aspects of kidney 
disease in women so that we may apply those learnings more broadly. Girls and women, who make 
up approximately 50% of the world’s population, are important contributors to society and their 
families. Gender differences continue to exist around the world in access to education, medical care, 
and participation in clinical studies. Pregnancy is a unique state for women, offering an opportunity 
for diagnosis of kidney disease, but also a state where acute and chronic kidney diseases may 
manifest, and which may impact future generations with respect to kidney health. There are various 
autoimmune and other conditions that are more likely to impact women with profound consequences 
for child bearing, and on the fetus. Women have different complications on dialysis than men, and 
are more likely to be donors than recipients of kidney transplants. In this editorial, we focus on what 
we do and do not know about women, kidney health, and kidney disease, and what we might learn in 
the future to improve outcomes worldwide. 
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Kidney Health and Women’s Health: a case for 
optimizing outcomes for present and future 
generations 
 
Introduction 
Chronic Kidney Disease (CKD) affects 
approximately 10% of the world’s adult 
population: it is within the top 20 causes of 
death worldwide [1], and its impact on patients 
and their families can be devastating. World 
Kidney Day and International Women’s Day 
in 2018 coincide, thus offering an opportunity 
to reflect on the importance of women’ s health 
and specifically their kidney health, on the 
community, and the next generations; as well 
as to strive to be more curious about the unique 
aspects of kidney disease in women, so that we 
may apply those learnings more broadly. 
Girls and women, who make up approximately 
50% of the world’s population, are important 
contributors to society and their families. 
Besides childbearing, women are essential in 
childrearing and contribute to sustaining 
family and community health. Women in the 
21st century continue to strive for equity in 
business, commerce, and professional 
endeavours, while recognizing that in many 
situations, equity does not exist. In various 
locations around the world, access to education 
and medical care is not equitable amongst men 
and women; women remain under-represented 
in many clinical research studies, thus limiting 
the evidence base on which to make 
recommendations to ensure best outcomes [Fig 
1].  
In this editorial, we focus on what we do and 
do not know about women’s kidney health and 
kidney disease, and what we might learn in the 
future to improve outcomes for all. 
 
What we know and do not know 
 
Pregnancy is a unique challenge and is a major 
cause of acute kidney injury (AKI) in women 
of childbearing age; AKI and pre-eclampsia 
(PE) may lead to subsequent CKD, but the 
entity of the risk is not completely known [2-
5]. CKD has a negative effect on pregnancy 
even at very early stages [6,7]. The risks 
increase with CKD progression thus posing 
potentially challenging ethical issues around 
conception and maintaining of pregnancies [6-
8]. We do know that PE increases the 
probability of hypertension and CKD in later 
years, but we have not evaluated a surveillance 
or reno-protective strategy to determine if 
progressive loss of kidney function can be 
attenuated [9-12]. 
Specific systemic conditions like Systemic 
Lupus Erythematosus (SLE), Rheumatoid 
Arthritis (RA), and Systemic Scleroderma 
(SS), are more likely to affect women than 
men. We do not know the relative contribution 
of these acute and chronic conditions on 
progression to end-stage renal disease (ESRD) 
in women. 
In CKD cohorts, the prevalence in women is 
always less than in men, and they have slower 
progression to ESRD [13-15]. We do not know 
why and how much of this is due to differences 
in identification of kidney impairment, 
different access to care, or true difference in 
disease severity and prevalence.
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Fig. 1. Sex differences throughout the continuum of CKD care 
 
different access to care, or true difference in 
disease severity and prevalence.  
Women with CKD have a higher 
cardiovascular risk than women without 
CKD [16]; but their risk is still lower than 
that of men with similar degrees of kidney 
impairment. In hemodialysis cohorts, there 
are differences in vascular access types in 
women versus men, which may be due to 
biological or systemic factors. In some 
locations there is differential use of 
peritoneal and hemodialysis in women and 
men. 
Women are more likely to donate kidneys 
for transplantation than to receive them. We 
do not know if this is because of the 
differential incidence of CKD in men vs 
women, cultural factors, or other reasons.  
There remain gender differences in access 
to care in different regions of the world, and 
we do not have data to directly evaluate the 
extent of these differences, in the poorest 
parts of the world in particular. 
 
Pregnancy, preeclampsia, pregnancy-
induced hypertensive disorders, and fetal 
health. The importance of women’s 
health to present and future kidney 
health 
 
What we know 
 
PE is the principal cause of AKI and 
maternal death, particularly in developing 
countries [2,17]. Pregnancy is the most 
common cause of AKI in women of 
childbearing age [10,18,19]. Several 
diseases and conditions, besides PE, 
hypertensive disorders of pregnancy, and 
CKD, can lead to pregnancy-related AKI. 
Causes vary in different regions. Septic 
abortion after an illegal procedure is the 
leading cause of early AKI in countries 
where legal abortions are not available, 
while PE after assisted fertilization is 
becoming a leading cause in developed 
countries [12,20,-22]. 
PE and hypertensive disorders of pregnancy 
occur in 3-10% of all pregnancies [2,3,18]; 
in these disorders the kidney is the main 
target of an unbalanced pro-angiogenic and 
anti-angiogenic derangement, leading to 
hypertension, proteinuria, and widespread 
endothelial damage. The incidence of PE, 
higher in low-middle income countries 
(possibly reflecting undiagnosed 
predisposing diseases), peaks at the 
extremes of reproductive age for reasons 
mentioned above [12,20-22]. 
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Fig. 2. Pregnancy and kidney function: complex interactions between 2 organs, the kidney and 
placenta. 
 
       
PE = preeclampsia; AKI = acute kidney injury; CKD = chronic kidney disease 
 
 
The relationship between kidney and placenta 
is biunivocal, and the presence of CKD is a risk 
factor for PE and hypertensive disorders of 
pregnancy [Fig. 2]. Besides CKD, other 
conditions cited as risk factors for PE 
(diabetes, immunologic diseases, baseline 
hypertension, obesity, and metabolic 
syndrome), are also risk factors for CKD. 
Given that even minor alterations of kidney 
function are present in many of these disorders, 
the importance of kidney function is indirectly 
recognized in the development of PE. Newer 
definitions of PE recognize differences 
between “placental” and “maternal” causes of 
PE, based on novel angiogenic-antiangiogenic 
markers [23,24], which may be important for 
management during and after pregnancy. 
There are long term effects of PE on both 
maternal and fetal health, but this remains an 
area of active research with many unknowns. 
 
PE is a risk factor for the future development 
of CKD and ESRD in the mother [3-5]. The 
reasons are not fully understood; podocyte loss 
is a hallmark of PE, suggesting permanent 
glomerular damage [25]. Endotheliosis, 
associated with PE, but also found in normal 
pregnancies, may herald glomerulosclerosis; 
tubular and vascular damage may co-exist 
[26,27]. 
Besides maternal risks, PE is associated with 
intrauterine and perinatal death, preterm 
delivery, and restricted intrauterine growth; the 
latter two are linked to “small babies” [2,3,5].
Placenta and kidney are highly 
vascularized; filter blood; divide 
compartments; are sophisticated 
metabolic machines
Pregnancy is a precious occasion 
to diagnose CKD.
From the placenta to the kidney
PE may induce permanent kidney damage, via 
AKI, tubular damage, podocyte loss
From the kidney to the placenta
CKD may induce placental dysfunction 
with an increased risk of pre-term 
delivery, hypertensive disorders of 
pregnancy and PE 
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Small babies and preterm babies have highly 
increased risks of neurological deficits and 
postnatal complications, especially sepsis [28-
32]. The risks may be higher in low-income 
countries, since survival and deficit-free 
survival depend on the provision of postnatal 
intensive care [20,21]. In the long term, small 
babies are at risk for the development of 
diabetes, metabolic syndrome, cardiovascular 
diseases (CVDs), and CKD in adulthood [33-
37]. Since kidney development is completed in 
the last phases of pregnancy, delayed, 
insufficient kidney growth, resulting in low 
nephron number is probably the basis of the 
increased risk of CKD and hypertension in 
small for gestational age, and preterm babies 
[33-37]. 
 
Pregnancy in chronic kidney disease, 
dialysis, and transplantation  
 
What we know 
 
Chronic kidney disease 
CKD is a risk factor for adverse pregnancy 
outcomes from its early stages [Table 1] 
[6,38,39]. The risks increase from CKD stage 
1 to CKD stage 5, and may be higher in 
glomerular nephropathies, autoimmune 
diseases, and diabetic nephropathy [6,7,38-
41]. Results of pregnancy after kidney 
donation suggest that reduction of kidney 
parenchyma may be associated with a higher 
risk of PE and hypertensive disorders of 
pregnancy [42,43]. 
Hypertension and proteinuria at baseline are 
important modulators of pregnancy-related 
risks; among the risks, we know that 
malformations are not increased with respect 
to the overall population (out of the context of 
inherited diseases, such as reflux nephropathy, 
  
 
polycystic kidney disease, or congenital 
anomalies of the kidney and urinary tract), 
maternal death is unusual (in highly resourced 
countries), while the incidence of preterm 
delivery and of small for gestational age 
babies, intrinsically linked, is increased in 
stage 1 CKD patients, and rises with the 
worsening of kidney function. Likewise, the 
effect of pregnancy on CKD progression is not 
fully understood because of different study 
designs, obstetric policies, and duration of 
follow-up. Overall, short- and long- term 
decrease in kidney function is unusual in early 
CKD, but the risk increases as CKD severity 
increases [6,7,38-41,44-48].  
Pregnancy is a potential occasion for the initial 
diagnosis of CKD. In poorly or unevenly 
resourced countries, advanced CKD may be 
discovered only during pregnancy. The 
implications of dialysis initiation may present 
important clinical and ethical issues; in highly 
resourced countries with established prenatal 
care, the diagnosis of earlier stages of CKD 
may lead to more intensive therapy and 
surveillance [49-51]. 
 
Dialysis and transplantation 
 
Fertility is reduced in ESRD; Australian and 
European data suggest a 1:10 ratio from 
general population to transplantation and from 
transplantation to dialysis (1:100 probability as 
compared to the general population) [52,53]. 
The first sporadic cases of successful 
pregnancy on dialysis were described in the 
70s, but in the new millennium this became an 
acknowledged real clinical possibility 
[8,54,55].  
More than 1000 pregnancies have been 
reported in dialysis patients [55]. The most 
important advance has been the demonstration
Piccoli et al. Ped Urol Case Rep 2018; 5(2):28-46            33 
 
Table1. Adverse pregnancy outcomes in patients with chronic kidney disease and in their 
offspring. 
 
 
SLE = Systemic Lupus Erythematosus; AKI = acute kidney injury; GFR = glomerular filtration rate; sCR = serum 
creatinine; CKD = chronic kidney disease; LLAC = Lupus-like anticoagulant; PE-AKI = preeclampsia acute 
kidney injury; SGA = small for gestational age; IUGR = intrauterine growth restriction; MMF = mycophenolate 
mofetil; mTor = mechanistic target of rapamycin; ACEi = angiotensin-converting-enzyme inhibitor; ARBS = 
angiotensin II receptor blockers; PKD = polycystic kidney disease; CAKUT = congenital anomalies of the kidney 
and urinary tract; IgA = immunoglobulin A 
Term Definition Main Issues 
Maternal death 
Death in pregnancy or 
within 1 week-1 month 
postpartum 
Too rare to be quantified, at least in highly resourced settings, where 
cases are in the setting of severe flares of immunologic diseases (SLE 
in primis). Still an issue in AKI; and in low resourced countries; not 
quantified in low-resourced countries, where it merges with dialysis 
need. 
CKD progression 
Decrease in GFR, rise in 
sCr, shift to a higher CKD 
stage 
Differently assessed and estimated; may be linked to obstetric policy 
(anticipating delivery in the case of worsening of the kidney function); 
between 20% and 80% in advanced CKD. Probably not increased in 
early CKD stages. 
Immunologic 
flares and 
neonatal SLE 
Flares of immunologic 
diseases in pregnancy 
Once thought to be increased in pregnancy, in particular in SLE, are 
probably a risk in patients who start pregnancy with an active disease, 
or with a recent flare-up. Definition of a “safe” zone is not uniformly 
agreed; in quiescent, well controlled diseases do not appear to be 
increased with respect to non-pregnant, carefully-matched controls. 
Transplant 
rejection  
Acute rejection in 
pregnancy 
Similar to SLE, rejection episodes are not increased with respect to 
matched controls; may be an issue in unplanned pregnancies, in 
unstable patients. 
Abortion  Fetal loss, before 21- 24 gestational weeks 
May be increased in CKD, but data are scant. An issue in immunologic 
diseases (eventually, but not exclusively linked to the presence of 
LLAC) and in diabetic nephropathy. 
Stillbirth  
Delivery of a nonviable 
infant, after 21-24 
gestational weeks  
Probably not increased in early CKD, maybe an issue in dialysis 
patients; when not linked to extreme prematurity, may specifically 
linked to SLE, immunologic diseases and diabetic nephropathy. 
Perinatal death Death within 1 week – 1 month form delivery 
Usually a result of extreme prematurity, which bears a risk of 
respiratory distress, neonatal sepsis, cerebral hemorrhage.  
Small, very small 
baby 
A baby weighting < 2500- 
1500 g at birth  Has to be analyzed with respect to gestational age. 
Preterm, early 
extremely preterm  
Delivery before 37 – 34 
or 28 completed 
gestational weeks 
Increase in risk of preterm and early preterm delivery across CKD 
stages; extremely preterm may be an important issue in undiagnosed 
or late referred CKD and PE-AKI. 
SGA (IUGR) < 5th or < 10th centile for gestational age 
Strictly and inversely related to pre-term delivery; SGA and IUGR are 
probably related to risk for hypertension, metabolic syndrome and CKD 
in adulthood. 
Malformations  Any kind of malformations 
Malformations are not increased in CKD patients not treated by 
teratogen drugs (MMF, mTor inhibitors, ACEi, ARBS); exception: 
diabetic nephropathy (attributed to diabetes); hereditary diseases, such 
as PKD, reflux nephropathy, CAKUT may be evident at birth. 
Hereditary kidney 
diseases Any kind of CKD  
Several forms of CKD recognize a hereditary pattern or predisposition; 
besides PKD, reflux and CAKUT, Alport’s disease, IgA, kidney tubular 
disorders and mitochondrial diseases have a genetic background, 
usually evident in adulthood and not always clearly elucidated. 
CKD - 
hypertension 
Higher risk of 
hypertension and CKD in 
adulthood 
Late maturation of nephrons results in a lower nephron number in 
preterm babies; the risks are probably higher in SGA-IUGR babies than 
in pre-term babies adequate for gestational age. 
Other long-term 
issues Developmental disorders 
Mainly due to prematurity, cerebral hemorrhage or neonatal sepsis, are 
not specific of CKD, but are a threat in all preterm babies. 
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of a strong relationship between the intensity 
(frequency and duration) of the dialysis 
sessions and positive pregnancy results: thus, 
intensifying dialysis up to daily, is the current 
standard of care [8,54]. Changing attitudes 
towards counselling women with advanced 
CKD may be impacted, with the knowledge of 
positive outcomes on dialysis for women and 
their offspring. 
Fertility is partly restored after kidney 
transplantation [56-60]. However, even in an 
ideal situation (normal kidney function, no 
hypertension or proteinuria, at least 2 years 
after transplantation, without recent rejection 
episodes), the risk of complications is higher in 
women with transplanted kidneys than in the 
general population. However, if teratogen 
drugs are avoided (mycophenolic acid and 
rapamycine), the outcomes of pregnancy after 
kidney transplantation shares the same risk 
factors as CKD (kidney function, 
hypertension, and proteinuria) [59]. 
Experience with pregnancy in patients with a 
reduced renal function or failing kidney graft 
is limited and counseling is still forcedly based 
on personal experience or indirect evidence 
[61,62]. Assisted fertilization techniques are 
increasingly popular in some settings, but 
dedicated studies in CKD patients are few; 
multiple pregnancies may bear an added risk in 
CKD patients, with both native and 
transplanted kidneys. 
 
Autoimmune diseases, women, and kidney 
disease 
 
What we know 
Autoimmune diseases such as SLE, RA, and 
SS preferentially affect women and are 
characterized by systemic inflammation 
leading to target organ  dysfunction,  including  
 
 
kidneys. Sex differences in the incidence and 
severity of these diseases result from a 
complex interaction of hormonal, genetic, and 
epigenetic factors [Table 2]. The public health 
burden of autoimmune diseases, which 
collectively represent a leading cause of 
morbidity and mortality among women 
throughout adulthood, is substantial [63-65]. 
SLE is an autoimmune disease with multiple 
organ involvement, affecting approximately 
five million people worldwide; 
disproportionately predominant in women (9:1 
female to male ratio) and individuals of non-
European ancestry. The highest female 
predominance (up to 15:1) is in peak 
reproductive years. The biology of these 
differences has been explored: one explanation 
is the number of X chromosomes and genetic 
variants on the X chromosome [66-68]; 
another important etiological explanation is the 
role of estrogen in SLE. Estrogen’s primary 
effects are mediated by transcription activity of 
the intracellular estrogen receptors, whose 
profile is altered in T-cells from female SLE 
patients [69,70]. Cathepsin S protein has 
recently been identified as a potential cause of 
lupus, triggering the immune system to attack 
healthy cells, particularly in females [71]. 
Numerous non-HLA genetic markers may 
predispose individuals of European, Hispanic, 
and Afro-American ancestry to lupus [72]. 
Susceptibility to SLE during pregnancy is also 
multifactorial; one factor being upregulation of 
IFN-α. Elevated IFN-α, expressed by the 
placenta, plays a pathogenic role in SLE, 
contributing both to the success of placental 
reproduction and to increased susceptibility to 
SLE [73]. Regulatory T-cells (which may be 
the key to cell modulating feto-maternal 
tolerance) have abnormalities of structure and 
function,   and  may   contribute  to  pregnancy
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Table 2. Sex differences in the incidence and severity of autoimmune diseases
Systemic Lupus Erythematosus; RA = Rheumatoid Arthritis; SS = Systemic Scleroderma 
pathology in women with SLE and to 
challenges of managing them during 
pregnancy [74]. SLE affects kidneys in about 
50% of patients, including glomerular, 
interstitial, and vascular lesions. Lupus 
nephritis is a major risk factor for overall 
morbidity and mortality in SLE, and despite 
potent therapies still leads to significant 
impairment of kidney function for many 
patients [75]. Kidney disease is a critical 
concern in counseling women with lupus 
considering pregnancy, with previous kidney 
involvement and lower C4 levels conferring 
high risk of active nephritis occurring in 
pregnancy [76]. Socioeconomic disparities are 
also linked to the health of patients with 
lupus. Poverty is associated with an increased 
long-term level of accumulated disease-
associated damage and a 1.67-times increased 
likelihood of experiencing a clinically 
meaningful increase in damage. Frequency of 
adverse pregnancy outcomes in women with 
lupus is twofold higher in black and Hispanic 
women than in white women. In blacks, 
socioeconomic status was a determinant of 
pregnancy outcomes and a key contributor to 
adverse pregnancy outcomes [77,78]. 
RA also preferentially affects women (4:1 ratio 
to men) with the peak incidence at age 45-55, 
coinciding with the perimenopausal years. 
This suggests a possible  association  between  
estrogen deficiency and disease onset. Female-
to-male incidence ratio after age 60 years is 
approximately 1:1, potentially implicating 
changes in sex hormones in the development 
of RA, and a pattern of RA symptom 
improvement or even remission during 
pregnancy is well recognized [79-81]. Renal 
involvement in RA is relatively common and 
multifactorial and is a predictor of mortality in 
RA patients. The risk of CKD is significantly 
higher in patients with RA than in the general 
population. The development of CKD may 
result from several ongoing processes, 
including specific renal involvement 
associated with RA (e.g., glomerulonephritis, 
interstitial nephritis), chronic inflammation, 
comorbidities, and nephrotoxic anti-rheumatic 
drugs. The strong association between RA 
activity and AA amyloidosis increases 
morbidity and is the main cause of ESRD with 
RA and nephropathy. Importantly, some of the 
life-long and combined RA pharmacotherapy 
can lead to various renal side effects [82-84]. 
SS predominantly affects women (female-to-
male ratios ranging from 3:1 to 14:1), with the 
peak incidence in the fifth and sixth decades. 
Estrogen may play a role in scleroderma 
pathogenesis through its stimulatory effect on 
transforming growth factor-beta 1 receptor and 
platelet-derived growth factor receptor [85]. 
Vasculopathy is  an  important disease-related
 SLE RA SS 
Peak Incidence Reproductive age Perimenopausal After 50-60 years 
Female/Male Ratio Peak 15:1 Peak 4:1 Peak 14:1 Total 9:1 After 60 years 1:1 Total 3:1 
Influence of 
Estrogen  
High levels Negative Positive ? 
Low levels ? Negative Negative 
Peccoli et al. Ped Urol Case Rep 2018; 5(2):28-46   36 
 
manifestations in affected women (86). SS 
can also be complicated by a number of 
different forms of kidney disease, including 
scleroderma renal crisis, which represents a 
form of malignant hypertension with acute 
renal failure; or more commonly ischemic 
nephropathy leading to slowly progressive 
CKD, accompanied by hypertension and 
albuminuria (78). Normotensive acute renal 
failure in patients with SS may be caused by 
interstitial nephritis or ANCA vasculitis, a 
separate entity in scleroderma with poor 
outcome (87-89). 
 
Women, chronic kidney disease, and access 
to renal replacement therapies 
 
What we know 
 
Although renal replacement therapy (RRT), 
including dialysis and transplantation is life-
sustaining, not all patients receive RRT. The 
rate of ESRD treated by RRT differs greatly 
between countries and regions, and intricately 
depends on the economy of a country and 
health care system (90,91). Worldwide, only 
50% of patients requiring RRT receive 
treatment (92), and in low and middle-income 
countries and regions, even less; in large parts 
of Sub-Saharan Africa, less than 2% of ESRD 
are treated by RRT (93). The equality of 
access to RRT for women and girls is of 
particular concern because, in many societies, 
they are disadvantaged by discrimination 
rooted in sociocultural factors (94,95). 
 
Sex differences in access to dialysis 
 
At least 2.284 million people may have died 
prematurely due to lack of access to RRT with 
treatment gaps being much larger in low-
income countries, with conservative estimates 
in Asia and Africa of 1.907 million and 
432,000 people not receiving RRT. By 2030, 
the estimated number of RRT should be more 
than double to 5.439 million (3.899–7.640 
million), with the most growth in Asia (0.968 
million to a projected 2.162 million [1.71–
3.14 million]) (92). These numbers are 
derived from an extensive systematic review. 
There are few data to compare the gender 
difference for the treatment gaps. Studies in 
Africa show that men were more likely to 
receive RRT than women (96,97). In Japan, 
the incidence of treated ESRD in females was 
less than half of that in males (3,287 in males 
vs. 1,764 women per million population 
treated) (91): no explanations are given for 
this finding. One US study reports women 
having significantly higher odds ratio of 1.70 
for late initiation of dialysis compared to men 
(98). Awareness levels of previous kidney 
disease in women were reported much lower 
than in men (2.9% ± 1.6% in women vs. 
17.9% ± 5.9% in men), which may contribute 
to later initiation of RRT (99). 
Mortality rates are similar in men and women 
on dialysis, but the incident rates of some 
dialysis-associated complications and 
morbidity are higher in women. A US report 
of hospitalizations in 111,653 patients 
undergoing maintenance hemodialysis 
describes higher hospitalization rates in 
women, and higher risk for 30-day 
readmissions (100). 
 
In addition, the prevalent use of arteriovenous 
fistula, which is associated with reduced 
mortality, complication, and costs, is lower 
among female than male hemodialysis 
patients (101). This may be due to a number 
of different factors, including 
anatomical/surgical issues relating to vessel 
size, timing of referral, and attitudinal 
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differences. This has not been systematically 
studied. 
Dialysis dose, which is evaluated by Kt/V 
may result in under-dialysis in women who 
have an average smaller volume of urea 
distribution or total body water than men 
(102). Women receiving dialysis have also 
been reported to have worse clinical 
parameters including anemia, nutrition, and 
quality of life (103). Reasons are not certain. 
 
Sex differences in access to kidney 
transplantation 
 
Transplantation represents the best form of 
RRT in patients without contraindications. 
Worldwide data describes that women are less 
likely than men to be kidney transplant 
recipients, either from a cadaveric or living 
donor, but are more likely to serve as living 
donors for kidney transplantation (104). Data 
from different countries, including the US, 
France, China, and India, confirm differential 
kidney transplant rates (lower in women than 
men), less likelihood of women being 
registered on national transplant waiting lists, 
and longer time from dialysis initiation to 
listing. Mothers are more likely to be donors, 
as are female spouses (91,105-108). Sex 
inequality also exists in the pediatric 
population. A survey from 35 countries 
participating in the European Society for 
Pediatric Nephrology/European Renal 
Association-European Dialysis and 
Transplant Association Registry, reported 
girls had a lower access to renal 
transplantation than boys (109).  
Socioeconomic factors undoubtedly play a 
role in the inequality of transplantation 
between sexes, especially in the low and 
middle-income countries and regions. 
Generally, men provide the major income for 
their family which may discourage them to 
donate kidneys. Different employment status 
and incomes between genders may contribute 
to sex differences in transplantation because 
employment and income status is usually 
associated with better healthcare insurance 
which cover the costs for transplantation. 
Psychosocial factors and education of women 
have been suggested as a contribution to sex 
disparity. US data found black women were 
less likely to want living donor kidney 
transplantation compared with men, despite 
being twice as likely as men to receive 
unsolicited offers for kidneys. They were also 
less likely to have been evaluated for a kidney 
transplant (110). Other reports describe 
disparities in age and sex in access to kidney 
transplantation which originate at the time of 
pre-referral discussions about kidney 
transplantation; irrespective of age, women 
were more likely not to have had discussions 
with medical professionals. This result may 
imply that there is a need for better clinical 
guidelines and education for women, their 
social network, and their providers (111). 
 
Present and future what we do not know 
 
Given the data presented above with respect 
to pregnancy, AKI, autoimmune diseases, 
CKD, dialysis and transplantation, there are 
many unanswered questions. In high income 
countries with increasing maternal age and 
assisted fertilization, there may be an increase 
in PE which may impact future generations if 
associated with adverse fetal outcomes. The 
increase in in-vitro fertilization techniques for 
those of advanced maternal age may lead to 
multiple pregnancies, which may predispose 
to PE, intrauterine growth restriction, or both. 
Will this lead to an increase in CKD and CVD 
for women in the future? 
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Due to the high heterogeneity of CKD, we do 
not know if and how pregnancy outcomes are 
modulated by the different nephropathies, as 
besides the most common ones such as IgA or 
lupus nephropathy, diabetic nephropathy, and 
reflux nephropathy, evidence is scant 
(44,45,112-114). How should we define 
preconception risks of pregnancy with respect 
to current proteinuria cut offs? Indications on 
when to start dialysis in pregnancy are not 
well established, nor is the specific role of 
frequency and duration. In those with kidney 
transplants, given the changing expanded 
donor policies, higher age at transplantation, 
and reduced fertility in older women, there 
may be changes in attitudes towards 
pregnancy with less than optimal kidney 
function (56,60). How this will impact short 
and long-term outcomes of mothers and their 
babies is not clear. 
Teen pregnancies are very common in some 
parts of the world, and are often associated 
with low income and cultural levels. The 
uneven legal rules for assisted fertilization and 
the lack of systematic assessment of the 
kidney function point to the need for further 
research. 
Despite elegant demonstrations for the role of 
sex hormones in vascular health and 
immunoregulation, the striking predominance 
in females of SLE, RA, and SS remains 
unexplained relative to other systemic 
diseases such as ANCA vasculitis and 
hemolytic-uremic syndrome. Note that 
thrombotic thrombocytopenic purpura has a 
higher incidence in women, though this is 
likely due to the association with other 
conditions more common in women. The 
incidence of kidney involvement in SLE 
during pregnancy and similarities/differences 
in those with PE have not been well studied. 
The role of different medications and 
responses to medications for autoimmune 
diseases relative to sex has also not been well 
studied.  
More attention to similarities between 
conditions, the importance of sex hormones in 
inflammation, immune-modulation, and 
vascular health, may lead to important 
insights and clinical breakthroughs over time. 
If women are more likely to be living donors, 
at differential ages, does this impact both 
CVD risk, and risk for ESKD: have we studied 
this well enough, in the current era, with 
modern diagnostic criteria for CKD and 
sophisticated tools to understand renal 
reserve? Are the additional exposures that 
women have after living donation 
compounded by hormonal changes on 
vasculature as they age? And are the risks of 
CKD and PE increased in the younger female 
kidney living donor? 
In the context of specific therapies for the 
treatment or delay of CKD progression, do we 
know if there are sex differences in 
therapeutic responses to ACEi/ARB? Should 
we look at dose finding/adjustments by sex? If 
vascular and immune biology is impacted by 
sex hormones as described earlier, do we 
know the impact of various therapies by level 
or ratio of sex hormones? In low-middle 
income countries how does changing 
economic and social cultures impact women’s 
health, and what is the nutritional impact on 
CKD of increasing predominance of obesity, 
diabetes, and hypertension? 
 
Summary 
 
Women have unique risks for kidney diseases: 
kidney diseases, as well as issues related to 
access to care, have a profound impact on both 
the current and next generations. Advocating 
for improved access to care for women is 
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critical to maintain the health of families, 
communities, and populations. 
Focused studies on the unique contribution of 
sex hormones, or the interaction of sex 
hormones and other physiology, is important 
to improve our understanding of the 
progression of kidney diseases. 
Immunological conditions such as pregnancy 
(viewed as a state of tolerance to non-self) as 
well as SLE and other autoimmune and 
systemic conditions common in women, 
better studied may also lead to breakthroughs 
in understanding and care paradigms. 
There is a clear need for higher awareness, 
timely diagnosis, and proper follow up of 
CKD in pregnancy. In turn, pregnancy may 
also be a valuable occasion for early diagnosis 
of CKD, allowing planning of therapeutic 
interventions. 
On this occasion, World Kidney Day and the 
International Women’s Day 2018 are 
commemorated on the same day, offering us 
the opportunity to highlight the importance of 
women’s health and particularly their kidney 
health. On its 13th anniversary, World Kidney 
Day promotes affordable and equitable access 
to health education, healthcare, and 
prevention for all women and girls in the 
world. 
The coinciding of World Kidney Day and 
International Women’s Day offers an 
opportunity to develop and define best 
practices and future research agendas, and 
ultimately, to optimize the outcomes of all 
people living with or at risk for kidney 
disease. 
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